DBV Technologies | DBVT - Gross Profit On Sales


DBV Technologies reported $2.77M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 23.17M 961K Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025